Morgan Stanley has a bold message for Johnson & Johnson
Johnson & Johnson (JNJ) has turned into one of the market’s steadier outperformers, with shares up roughly 55% over the past year as investors gain confidence in the company’s ability to grow beyond STELARA. Now, Morgan Stanley believes the healthcare giant may still have room to run. The firm …
Read MoreJ&J’s First-Quarter Sales Grow on Cancer-Drug Strength
The drug and medical-device maker has been working to ensure consistent growth after losing patent protection for its blockbuster Stelara.
Read More